TY - JOUR
T1 - Ceftizoxime plus ticarcillin
T2 - Double β-lactam therapy for infections in cancer patients
AU - Rolston, Kenneth V.I.
AU - Jones, Paula G.
AU - Fainstein, Victor
AU - Elting, Linda
AU - Bodey, Gerald P.
PY - 1987/3/1
Y1 - 1987/3/1
N2 - Eighty-one febrile episodes in cancer patients with adequate neutrophil counts (>1000/μl) were treated with a double β-lactam combination of ceftizoxime plus ticarcillin. Fifty-four episodes were microbiologically documented and 27 were clinically documented. The overall response rate was 75% (61 of 81). The response rate in 38 episodes where a single organism was identified was 71%. Polymicrobial infections were associated with a high response rate of 87%. Responses occurred in six of eight Gram-positive and 21 of 30 Gram-negative infections. Pneumonia was the most frequent infection and was associated with a response of 61%. Septicaemia and urinary tract infections also occurred commonly and had response rates of 76% and 89% respectively. All but one organism were susceptible to at least one of the antibiotics. No resistant organisms emerged during therapy. Side-effects included rash (1), phlebitis (3), and coagulation abnormalities without bleeding (3). Four patients developed superinfections (three bacterial, one fungal). The double β-lactam combination of ceftizoxime plus ticarcillin was safe and effective therapy for infections in non-neutropenic cancer patients.
AB - Eighty-one febrile episodes in cancer patients with adequate neutrophil counts (>1000/μl) were treated with a double β-lactam combination of ceftizoxime plus ticarcillin. Fifty-four episodes were microbiologically documented and 27 were clinically documented. The overall response rate was 75% (61 of 81). The response rate in 38 episodes where a single organism was identified was 71%. Polymicrobial infections were associated with a high response rate of 87%. Responses occurred in six of eight Gram-positive and 21 of 30 Gram-negative infections. Pneumonia was the most frequent infection and was associated with a response of 61%. Septicaemia and urinary tract infections also occurred commonly and had response rates of 76% and 89% respectively. All but one organism were susceptible to at least one of the antibiotics. No resistant organisms emerged during therapy. Side-effects included rash (1), phlebitis (3), and coagulation abnormalities without bleeding (3). Four patients developed superinfections (three bacterial, one fungal). The double β-lactam combination of ceftizoxime plus ticarcillin was safe and effective therapy for infections in non-neutropenic cancer patients.
UR - http://www.scopus.com/inward/record.url?scp=0023139825&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0023139825&partnerID=8YFLogxK
U2 - 10.1093/jac/19.3.367
DO - 10.1093/jac/19.3.367
M3 - Article
C2 - 3471752
AN - SCOPUS:0023139825
VL - 19
SP - 367
EP - 371
JO - Journal of Antimicrobial Chemotherapy
JF - Journal of Antimicrobial Chemotherapy
SN - 0305-7453
IS - 3
ER -